Press Release: Biodesix Announces Third Quarter 2024 Results and Highlights

Dow Jones

Nov 01, 2024

 basic and diluted      146,296       79,709    123,634       78,672 
 
 
                           Biodesix, Inc. 
      Reconciliation of Net Loss to Adjusted EBITDA (unaudited) 
                            (in thousands) 
 
                      Three Months Ended       Nine Months Ended 
                         September 30,           September 30, 
                     ---------------------   --------------------- 
                       2024        2023        2024        2023 
                     --------   ----------   --------   ---------- 
Net loss             $(10,258)  $  (10,949)  $(34,680)  $  (43,007) 
    Interest 
     expense            2,041        2,386      6,506        7,207 
    Depreciation 
     and 
     amortization       1,492          782      4,324        2,351 
    Share-based 
     compensation 
     expense            1,515          954      5,373        4,292 
    Loss on 
    extinguishment 
    of liabilities         --           --        248           -- 
    COVID-19 
     Revenue               --           --         --          (13) 
    COVID-19 Direct 
     costs and 
     expenses              --           --         --            1 
    Change in fair 
     value of 
     warrant 
     liability, 
     net                   --        1,393         --        1,332 
    Other expense 
     (income), net       (374)          (2)        77           (4) 
                      -------    ---------    -------    --------- 
Adjusted EBITDA      $ (5,584)  $   (5,436)  $(18,152)  $  (27,841) 
                      =======    =========    =======    =========

(END) Dow Jones Newswires

November 01, 2024 06:00 ET (10:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2480077712"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480077712\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2480077712?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480077712","market":"hk","top_or_hot":-1,"title":"Press Release: Biodesix Announces Third Quarter 2024 Results and Highlights","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n basic and diluted      146,296       79,709    123,634       78,672 \n \n \n                           <a href=\"https://laohu8.com/S/BDSX\">Biodesix, Inc.</a> \n      Reconciliation of Net Loss to Adjusted EBITDA (unaudited) \n                            (in thousands) \n \n                      Three Months Ended       Nine Months Ended \n                         September 30,           September 30, \n                     ---------------------   --------------------- \n                       2024        2023        2024        2023 \n                     --------   ----------   --------   ---------- \nNet loss             $(10,258)  $  (10,949)  $(34,680)  $  (43,007) \n    Interest \n     expense            2,041        2,386      6,506        7,207 \n    Depreciation \n     and \n     amortization       1,492          782      4,324        2,351 \n    Share-based \n     compensation \n     expense            1,515          954      5,373        4,292 \n    Loss on \n    extinguishment \n    of liabilities         --           --        248           -- \n    COVID-19 \n     Revenue               --           --         --          (13) \n    COVID-19 Direct \n     costs and \n     expenses              --           --         --            1 \n    Change in fair \n     value of \n     warrant \n     liability, \n     net                   --        1,393         --        1,332 \n    Other expense \n     (income), net       (374)          (2)        77           (4) \n                      -------    ---------    -------    --------- \nAdjusted EBITDA      $ (5,584)  $   (5,436)  $(18,152)  $  (27,841) \n                      =======    =========    =======    ========= \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 06:00 ET (10:00 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Biodesix Announces Third Quarter 2024 Results and Highlights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Biodesix Announces Third Quarter 2024 Results and Highlights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-01 18:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n basic and diluted      146,296       79,709    123,634       78,672 \n \n \n                           <a href=\"https://laohu8.com/S/BDSX\">Biodesix, Inc.</a> \n      Reconciliation of Net Loss to Adjusted EBITDA (unaudited) \n                            (in thousands) \n \n                      Three Months Ended       Nine Months Ended \n                         September 30,           September 30, \n                     ---------------------   --------------------- \n                       2024        2023        2024        2023 \n                     --------   ----------   --------   ---------- \nNet loss             $(10,258)  $  (10,949)  $(34,680)  $  (43,007) \n    Interest \n     expense            2,041        2,386      6,506        7,207 \n    Depreciation \n     and \n     amortization       1,492          782      4,324        2,351 \n    Share-based \n     compensation \n     expense            1,515          954      5,373        4,292 \n    Loss on \n    extinguishment \n    of liabilities         --           --        248           -- \n    COVID-19 \n     Revenue               --           --         --          (13) \n    COVID-19 Direct \n     costs and \n     expenses              --           --         --            1 \n    Change in fair \n     value of \n     warrant \n     liability, \n     net                   --        1,393         --        1,332 \n    Other expense \n     (income), net       (374)          (2)        77           (4) \n                      -------    ---------    -------    --------- \nAdjusted EBITDA      $ (5,584)  $   (5,436)  $(18,152)  $  (27,841) \n                      =======    =========    =======    ========= \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 06:00 ET (10:00 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4555","symbol_name":"新能源车","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480077712","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480077712","pubTimestamp":1730455200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million;Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023;Q3 2024 Net loss improved by 6% compared to Q3 2023;\"The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals - driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation of operational efficiencies, and maintaining a cost-disciplined approach as we drive our business to profitability,\" said Scott Hutton, CEO of Biodesix.Third Quarter Ended September 30, 2024 Business Highlights. Nodify CDT and Nodify XL2 tests in diverse patient subgroups","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4555":"新能源车","BDSX":"Biodesix, Inc.","R":"瑞德系统","03160":"华夏日股对冲","TM":"丰田汽车","BK4022":"陆运","BK4099":"汽车制造商","BK4588":"碎股","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念","BK4232":"货物陆运"},"translate_title":"新闻稿：Biodesix公布2024年第三季度业绩和亮点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDSX":1,"R":1,"TM":1,"03160":0.6},"content_text":"basic and diluted      146,296       79,709    123,634       78,672 \n \n \n                           Biodesix, Inc. \n      Reconciliation of Net Loss to Adjusted EBITDA (unaudited) \n                            (in thousands) \n \n                      Three Months Ended       Nine Months Ended \n                         September 30,           September 30, \n                     ---------------------   --------------------- \n                       2024        2023        2024        2023 \n                     --------   ----------   --------   ---------- \nNet loss             $(10,258)  $  (10,949)  $(34,680)  $  (43,007) \n    Interest \n     expense            2,041        2,386      6,506        7,207 \n    Depreciation \n     and \n     amortization       1,492          782      4,324        2,351 \n    Share-based \n     compensation \n     expense            1,515          954      5,373        4,292 \n    Loss on \n    extinguishment \n    of liabilities         --           --        248           -- \n    COVID-19 \n     Revenue               --           --         --          (13) \n    COVID-19 Direct \n     costs and \n     expenses              --           --         --            1 \n    Change in fair \n     value of \n     warrant \n     liability, \n     net                   --        1,393         --        1,332 \n    Other expense \n     (income), net       (374)          (2)        77           (4) \n                      -------    ---------    -------    --------- \nAdjusted EBITDA      $ (5,584)  $   (5,436)  $(18,152)  $  (27,841) \n                      =======    =========    =======    ========= \n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 06:00 ET (10:00 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}